Clin2
NCT07484243Possibly a fitRecruiting

Chinese and Western medicine for rheumatoid arthritis

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung DiseaseDifficult-to-Treat Rheumatoid Arthritis

Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.

This study combines traditional Chinese medicine with Western medicine to treat rheumatoid arthritis. It aims to see how well this approach works for people with hard-to-treat RA or RA-related lung disease.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
10,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be at least 18 years old.
  • You need a diagnosis of rheumatoid arthritis using standard medical criteria.
  • If your RA is difficult to treat, it must meet specific guidelines for hard-to-treat RA.
  • If you have RA-related lung disease, both a rheumatologist and a lung doctor must confirm it.
  • You must be willing to receive traditional Chinese medicine treatments.
  • You cannot have serious health issues like cancer, severe lung problems, or active infections.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07721142Recruiting· Phase 4
Chinese medicine and Western medicine for hard-to-treat rheumatoid arthritis

This trial combines traditional Chinese herbal medicine with standard Western treatments for people with rheumatoid arthritis that hasn't responded well to at least two prior medications. It aims to see if the combination is more effective and safe.

Shanghai
NCT07643038Not yet recruiting· Phase 4
Treatment strategy for rheumatoid arthritis with lung scarring

This study tests a treatment plan for people who have rheumatoid arthritis and interstitial lung disease (scarring in the lungs). The goal is to find the best way to treat both conditions together and slow lung damage.

Luoyang, Henan
NCT07748728Not yet recruiting· Phase 2
Study of TLL-018 for rheumatoid arthritis after standard treatments fail

This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.

Beijing, Beijing Municipality
NCT07008196Not yet recruiting· Phase 4
Telitacicept for hard-to-treat rheumatoid arthritis

This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.

Beijing
NCT06309030Not yet recruiting
Chinese herbal formula for rheumatoid arthritis with kidney deficiency

This trial tests a Chinese herbal formula (Bushen Quhan Zhiwang decoction) to help people with rheumatoid arthritis who also have a pattern of 'kidney deficiency and excessive cold' achieve deeper remission. It may be an option if your disease is mild to moderate and you are on a stable single medication.

NCT07115641Not yet recruiting
Huoluo pills plus iguratimod for rheumatoid arthritis

This trial tests a combination of a traditional Chinese medicine (Huoluo Pills) and a Western drug (iguratimod) for people with moderate rheumatoid arthritis. It aims to see if the combination works better than either treatment alone.

Hear when a new Rheumatoid Arthritis-Associated Interstitial Lung Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.